<?xml version="1.0" encoding="UTF-8"?>
<ref id="B119-pharmaceutics-13-00387">
 <label>119.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Van Der Vossen</surname>
    <given-names>A.C.</given-names>
   </name>
   <name>
    <surname>Van Der Velde</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Smeets</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Postma</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Eckhardt</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Vermes</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Koch</surname>
    <given-names>B.C.P.</given-names>
   </name>
   <name>
    <surname>Vulto</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Hanff</surname>
    <given-names>L.</given-names>
   </name>
  </person-group>
  <article-title>Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug</article-title>
  <source>Eur. J. Pharm. Sci.</source>
  <year>2017</year>
  <volume>100</volume>
  <fpage>205</fpage>
  <lpage>210</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ejps.2017.01.025</pub-id>
  <?supplied-pmid 28126558?>
  <pub-id pub-id-type="pmid">28126558</pub-id>
 </element-citation>
</ref>
